Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL27471205 | 0.97 | OPRM1 (0.40) | OPRM1HTR2ADRD4SIGMAR1DRD2 | |
| SCHEMBL28287844 | 0.91 | OPRM1 (0.37) | OPRM1HTR2ADRD4SIGMAR1ALDH1A1 | |
| SCHEMBL6371585 | 0.90 | FAAH (0.39) | OPRM1MEN1KMT2A | |
| Pyridine SCHEMBL28101957 | 0.84 | CYP1A2 (0.33) | OPRM1HTR2AALDH1A1KMT2ASLC6A4 | |
| SCHEMBL5915111 | 0.82 | OPRM1 (0.40) | OPRM1HTR2ASIGMAR1DRD2 | |
| SCHEMBL5915123 | 0.80 | OPRM1 (0.39) | OPRM1HTR2ASIGMAR1DRD2ALDH1A1 | |
| SCHEMBL7245634 | 0.78 | HTR2A (0.44) | OPRM1HTR2ADRD4SIGMAR1MEN1 | |
| Alcohol SCHEMBL27819586 | 0.78 | HTR2A (0.39) | OPRM1HTR2ADRD4SIGMAR1SLC22A1 | |
| SCHEMBL8223305 | 0.74 | FAAH (0.38) | OPRM1HTR2ASIGMAR1MEN1ALDH1A1 | |
| SCHEMBL28269595 | 0.74 | ALDH1A1 (0.39) | OPRM1HTR2AMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030120-B2 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | OPRM1 513/4885HTR2A 1170/4885DRD4 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.